Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22445348 | 0.86 | LPL (0.33) | FFAR1UCHL1GSK3AGSK3B | |
| SCHEMBL30907260 | 0.79 | DGAT1 (0.37) | UCHL1GSK3AGSK3B | |
| SCHEMBL19949147 | 0.78 | GSK3A (0.32) | UCHL1GSK3AGSK3B | |
| SCHEMBL16754496 | 0.78 | UHRF1 (0.39) | FFAR1 | |
| SCHEMBL29977691 | 0.78 | UHRF1 (0.39) | FFAR1 | |
| SCHEMBL19949149 | 0.77 | DGAT1 (0.36) | UCHL1GSK3AGSK3B | |
| SCHEMBL28360858 | 0.76 | DGAT1 (0.35) | FFAR1UCHL1GSK3AGSK3B | |
| SCHEMBL16754600 | 0.76 | LIPE (0.30) | — | |
| SCHEMBL19744093 | 0.76 | SIRT6 (0.37) | FFAR1UCHL1GSK3AGSK3B | |
| SCHEMBL14245043 | 0.76 | CHRNB2 (0.31) | UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601284-B1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3601284-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183956-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | FFAR1 4729/4885UCHL1 3869/4885ABL1 2720/4885 |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | NEK1, NEK5, NEK11 | FFAR1 4729/4885UCHL1 3869/4885ABL1 2720/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | FFAR1 4729/4885UCHL1 3869/4885ABL1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.